ADVERTISEMENT

Lupin Q1 Review - Ex-Milestone Income, Disappointing Quarter, U.S. To Kick From FY23/24E: Dolat Capital

Lupin Q1 Review - Ex-Milestone Income, Disappointing Quarter, U.S. To Kick From FY23/24E: Dolat Capital

Duloxetine delayed-release capsules sit inside a bottle beside other empty bottles inside the packaging unit at the Lupin Ltd. (Photographer: Dhiraj Singh/Bloomberg)  
Duloxetine delayed-release capsules sit inside a bottle beside other empty bottles inside the packaging unit at the Lupin Ltd. (Photographer: Dhiraj Singh/Bloomberg)  
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More